Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct;30(10):2771-2776.
doi: 10.1038/s41591-024-03189-y. Epub 2024 Jul 16.

Licensed H5N1 vaccines generate cross-neutralizing antibodies against highly pathogenic H5N1 clade 2.3.4.4b influenza virus

Surender Khurana  1 , Lisa R King  2 , Jody Manischewitz  2 , Olivia Posadas  2 , Ashish K Mishra  2 , Dongxiao Liu  2 , John H Beigel  3 , Rino Rappuoli  4 , John S Tsang  5   6   7 , Hana Golding  2
Affiliations

Licensed H5N1 vaccines generate cross-neutralizing antibodies against highly pathogenic H5N1 clade 2.3.4.4b influenza virus

Surender Khurana et al. Nat Med. 2024 Oct.

Abstract

The emergence of highly pathogenic avian influenza (HPAI) H5N1 clade 2.3.4.4b viruses and their transmission to dairy cattle and animals, including humans, poses a major global public health threat. Therefore, the development of effective vaccines and therapeutics against H5N1 clade 2.3.4.4b virus is considered a public health priority. In the United States, three H5N1 vaccines derived from earlier strains of HPAI H5N1 (A/Vietnam, clade 1, and A/Indonesia, clade 2.1) virus, with (MF59 or AS03) or without adjuvants, are licensed and stockpiled for pre-pandemic preparedness, but whether they can elicit neutralizing antibodies against circulating H5N1 clade 2.3.4.4b viruses is unknown. In this study, we evaluated the binding, hemagglutination inhibition and neutralizing antibody response generated after vaccination of adults with the three licensed vaccines. Individuals vaccinated with the two adjuvanted licensed H5N1 vaccines generated cross-reactive binding and cross-neutralizing antibodies against the HPAI clade 2.3.4.4b A/Astrakhan/3212/2020 virus. Seroconversion rates of 60-95% against H5 clade 2.3.4.4b were observed after two doses of AS03-adjuvanted-A/Indonesia or three doses of MF59-adjuvanted-A/Vietnam vaccine. These findings suggest that the stockpiled US-licensed adjuvanted H5N1 vaccines generate cross-neutralizing antibodies against circulating HPAI H5N1 clade 2.3.4.4b in humans and may be useful as bridging vaccines until updated H5N1 vaccines become available.

PubMed Disclaimer

References

    1. Abbasi, J. Bird flu outbreak in dairy cows is widespread, raising public health concerns. JAMA 331, 1789–1791 (2024).
    1. Burrough, E. R. et al. Highly pathogenic avian influenza A(H5N1) clade 2.3.4.4b virus infection in domestic dairy cattle and cats, United States, 2024. Emerg. Infect. Dis. 30, 1335–1343 (2024). - DOI - PMC - PubMed
    1. Cohen, J. Worries about bird flu in U.S. cattle intensify. Science 384, 12–13 (2024). - DOI - PubMed
    1. Uyeki, T. M. et al. Highly pathogenic avian influenza A(H5N1) virus infection in a dairy farm worker. N. Engl. J. Med. 390, 2028–2089 (2024).
    1. Centers for Disease Control and Prevention. CDC A(H5N1) Bird Flu Response Update June 28, 2024. https://www.cdc.gov/bird-flu/spotlights/h5n1-response-06282024.html#:~:t... (2024).

LinkOut - more resources